BR112018015125A2 - ?derivado de amina cíclica, medicamento, antagonista do receptor órfão ¿ relacionado com retinoide, e, agente terapêutico ou agente preventivo? - Google Patents

?derivado de amina cíclica, medicamento, antagonista do receptor órfão ¿ relacionado com retinoide, e, agente terapêutico ou agente preventivo?

Info

Publication number
BR112018015125A2
BR112018015125A2 BR112018015125-4A BR112018015125A BR112018015125A2 BR 112018015125 A2 BR112018015125 A2 BR 112018015125A2 BR 112018015125 A BR112018015125 A BR 112018015125A BR 112018015125 A2 BR112018015125 A2 BR 112018015125A2
Authority
BR
Brazil
Prior art keywords
retinoid
receptor antagonist
amine derivative
cyclic amine
therapeutic
Prior art date
Application number
BR112018015125-4A
Other languages
English (en)
Inventor
Hayashi Shinnosuke
VALLET Martial
YOKOSAKA Shinya
Osumi Kazuya
Aoki Takumi
Meguro Hiroyuki
Kaino Mie
TAKAGAKI Kozue
Takahashi Takehiro
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Publication of BR112018015125A2 publication Critical patent/BR112018015125A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Toys (AREA)
  • Portable Nailing Machines And Staplers (AREA)

Abstract

o propósito da presente invenção é fornecer um novo composto tendo atividade antagonista contra o receptor órfão ¿ relacionado com retinoide e exibir um efeito terapêutico ou um efeito preventivo para uma doença autoimune tal como esclerose múltipla ou psoríase ou uma doença alérgica tal como dermatite de contato, dermatite atópica ou outra dermatite alérgica. a presente invenção fornece um derivado de amina cíclica representado pela fórmula ou um sal do mesmo farmaceuticamente aceitável.
BR112018015125-4A 2016-01-29 2017-01-27 ?derivado de amina cíclica, medicamento, antagonista do receptor órfão ¿ relacionado com retinoide, e, agente terapêutico ou agente preventivo? BR112018015125A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016015512 2016-01-29
JP2016-015512 2016-01-29
JP2016-212629 2016-10-31
JP2016212629 2016-10-31
PCT/JP2017/002924 WO2017131156A1 (ja) 2016-01-29 2017-01-27 環状アミン誘導体及びその医薬用途

Publications (1)

Publication Number Publication Date
BR112018015125A2 true BR112018015125A2 (pt) 2019-02-26

Family

ID=59398579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015125-4A BR112018015125A2 (pt) 2016-01-29 2017-01-27 ?derivado de amina cíclica, medicamento, antagonista do receptor órfão ¿ relacionado com retinoide, e, agente terapêutico ou agente preventivo?

Country Status (23)

Country Link
US (1) US10364222B2 (pt)
EP (1) EP3409660B1 (pt)
JP (1) JP6807054B2 (pt)
KR (1) KR20180100573A (pt)
CN (1) CN108473426B (pt)
AU (1) AU2017210685B2 (pt)
BR (1) BR112018015125A2 (pt)
CA (1) CA3009971C (pt)
DK (1) DK3409660T3 (pt)
ES (1) ES2822606T3 (pt)
HU (1) HUE050744T2 (pt)
IL (1) IL260230B (pt)
MX (1) MX2018008454A (pt)
MY (1) MY195416A (pt)
PH (1) PH12018501434A1 (pt)
PL (1) PL3409660T3 (pt)
PT (1) PT3409660T (pt)
RU (1) RU2696862C1 (pt)
SG (1) SG11201805474PA (pt)
TR (1) TR201912580U5 (pt)
TW (1) TWI691486B (pt)
WO (1) WO2017131156A1 (pt)
ZA (1) ZA201804325B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881649B2 (en) 2017-07-27 2021-01-05 Toray Industries, Inc. Therapeutic agent or preventive agent for alopecia areata
WO2019022234A1 (ja) * 2017-07-27 2019-01-31 東レ株式会社 炎症性腸疾患の治療剤又は予防剤
TW201910312A (zh) * 2017-07-28 2019-03-16 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
TW201920137A (zh) * 2017-08-31 2019-06-01 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
KR20200115491A (ko) 2018-01-31 2020-10-07 도레이 카부시키가이샤 환상 아민 유도체 및 그 의약 용도
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
CA3093695A1 (en) 2018-03-12 2019-09-19 Escalier Biosciences B.V. Spirocyclic ror-gamma modulators
CN111548303A (zh) * 2020-06-28 2020-08-18 山东美泰医药有限公司 一种盐酸左布比卡因的杂质及其制备和分析方法
CN113252831B (zh) * 2021-05-20 2022-08-26 京博农化科技有限公司 N-氯甲酰基-n-[4-（三氟甲氧基）苯基]氨基甲酸甲酯超高效液相色谱分析方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563522A (en) * 2005-04-22 2010-01-29 Daiichi Sankyo Co Ltd Heterocyclic compound with immunosuppressive activity
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
KR20100098683A (ko) * 2007-12-12 2010-09-08 아스트라제네카 아베 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도
PE20110105A1 (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1
JP5705748B2 (ja) * 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
CA2816753A1 (en) 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
PE20141637A1 (es) 2011-04-28 2014-11-20 Japan Tobacco Inc Compuesto de amida y aplicacion farmaceutica para el mismo
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
GB201207406D0 (en) * 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
CN104603118B (zh) 2012-05-31 2017-10-03 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物
KR20150127245A (ko) * 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
JP6548664B2 (ja) * 2014-01-06 2019-07-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ シクロヘキシルスルホンＲＯＲγ調節因子
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
JPWO2015129853A1 (ja) * 2014-02-27 2017-03-30 東レ株式会社 環状アミン誘導体及びその医薬用途

Also Published As

Publication number Publication date
PT3409660T (pt) 2020-07-31
KR20180100573A (ko) 2018-09-11
TR201912580U5 (tr) 2020-09-21
SG11201805474PA (en) 2018-07-30
CN108473426B (zh) 2021-09-07
CA3009971C (en) 2024-03-19
JP6807054B2 (ja) 2021-01-06
CA3009971A1 (en) 2017-08-03
AU2017210685A1 (en) 2018-07-05
ES2822606T3 (es) 2021-05-04
MY195416A (en) 2023-01-20
RU2696862C1 (ru) 2019-08-07
TW201731816A (zh) 2017-09-16
WO2017131156A1 (ja) 2017-08-03
CN108473426A (zh) 2018-08-31
IL260230A (en) 2018-07-31
HUE050744T2 (hu) 2021-01-28
MX2018008454A (es) 2018-08-14
ZA201804325B (en) 2019-09-25
US10364222B2 (en) 2019-07-30
PL3409660T3 (pl) 2021-01-25
PH12018501434A1 (en) 2019-03-04
US20180370916A1 (en) 2018-12-27
EP3409660A1 (en) 2018-12-05
IL260230B (en) 2020-06-30
EP3409660A4 (en) 2019-06-26
JPWO2017131156A1 (ja) 2018-11-22
DK3409660T3 (da) 2020-08-31
AU2017210685B2 (en) 2020-09-24
EP3409660B1 (en) 2020-07-01
TWI691486B (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
BR112018015125A2 (pt) ?derivado de amina cíclica, medicamento, antagonista do receptor órfão ¿ relacionado com retinoide, e, agente terapêutico ou agente preventivo?
BR112015020302A2 (pt) derivado de pirazol
BR112018000906A2 (pt) ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto?
BR112018067312A2 (pt) compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
BR112015020008A2 (pt) compostos de biaril amida como inibidores de cinase
BR112015019921A2 (pt) composto inibidor de trk
UY35612A (es) Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112017014740A2 (pt) composto espiro tricíclico
BR112013027883A2 (pt) novo derivado de 1-óxido de 3-hidroxiisotiazol
BR112018015389A2 (pt) derivado de 5-etil-4-metil-pirazol-3-carboxamida tendo atividade como agonista de taar
BR112012004851B8 (pt) uso de um derivado de tiazol
BR112016013425A2 (pt) Composto e composição farmacêutica
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
NZ730475A (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
TN2016000491A1 (en) Carboxamide derivatives.
BR112015019919A2 (pt) compostos bicíclicos
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
BR112022008367A2 (pt) Antagonistas heterocíclicos de nmda
ECSP22054240A (es) Compuesto y composici?n como inhibidor de quinasa del receptor pdgf
BR112015015663A2 (pt) novo derivado de benzoazepina e uso médico do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]